{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:44:06Z","timestamp":1784774646348,"version":"3.55.0"},"reference-count":203,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018429","name":"Istituto Europeo di Oncologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023228","name":"Indigenous Bar Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023228","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.radonc.2024.110264","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T23:40:24Z","timestamp":1711842024000},"page":"110264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"195","author":[{"given":"Giulia","family":"Corrao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marvaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Mastroleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Minari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Vincini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Zerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Gaito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Carlo","family":"Mazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cattani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Petralia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Musi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Orecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Alterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110264_b0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1016\/j.radonc.2024.110264_b0010","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2024.110264_b0020","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0025","first-page":"1288","article-title":"NCCN guidelines\u00ae insights: prostate cancer, version 1.2023","volume":"20","author":"Schaeffer","year":"2022","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.1016\/j.radonc.2024.110264_b0030","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.pcan.4500987","article-title":"Particle therapy in prostate cancer: a review","volume":"10","author":"Greco","year":"2007","journal-title":"Prostate Cancer and Prostatic Diseases"},{"key":"10.1016\/j.radonc.2024.110264_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14338\/IJPT-20-00031.1","article-title":"Consensus statement on proton therapy for prostate cancer","volume":"8","author":"Bryant","year":"2021","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.radonc.2024.110264_b0045","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3390\/cancers13061468","article-title":"Charged particle and conventional radiotherapy: current implications as partner for immunotherapy","volume":"13","author":"Marcus","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2024.110264_b0050","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ijrobp.2016.02.038","article-title":"Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate cancer","volume":"95","author":"Bryant","year":"2016","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0055","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijrobp.2003.10.011","article-title":"Proton therapy for prostate cancer: the initial Loma Linda University experience","volume":"59","author":"Slater","year":"2004","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0060","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.ijrobp.2020.11.007","article-title":"Proton therapy for localized prostate cancer: long-term results from a single-center experience","volume":"109","author":"Takagi","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0065","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.radonc.2024.110264_b0070","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2024.110264_b0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/emermed-2020-209567","article-title":"Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews","volume":"37","author":"Amir-Behghadami","year":"2020","journal-title":"Emergency Medicine Journal"},{"key":"10.1016\/j.radonc.2024.110264_b0080","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. 2021. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"10.1016\/j.radonc.2024.110264_b0085","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (RTOG) and the european Organization for Research and Treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0090","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0095","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.radonc.2024.110264_b0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"European Journal of Epidemiology"},{"key":"10.1016\/j.radonc.2024.110264_b0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2024.110264_b0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.radonc.2024.110264_b0115","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2024.110264_b0120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2024.110264_b0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14338\/IJPT-20-00094.1","article-title":"Proton therapy of prostate and pelvic lymph nodes for high risk prostate cancer: acute toxicity","volume":"8","author":"Choo","year":"2021","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.radonc.2024.110264_b0130","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ijrobp.2019.05.069","article-title":"Four-year outcomes from a prospective phase II clinical trial of moderately hypofractionated proton therapy for localized prostate cancer","volume":"105","author":"Grewal","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0135","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/0284186X.2021.2016948","article-title":"Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer","volume":"61","author":"Henderson","year":"2022","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.radonc.2024.110264_b0140","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/0284186X.2013.764011","article-title":"A phase II study of hypofractionated proton therapy for prostate cancer","volume":"52","author":"Kim","year":"2013","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.radonc.2024.110264_b0145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10147-017-1209-8","article-title":"Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer","volume":"23","author":"Nakajima","year":"2018","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0150","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/cancers10040116","article-title":"Proton beam therapy alone for intermediate- or high-risk prostate cancer: an institutional prospective cohort study","volume":"10","author":"Arimura","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2024.110264_b0155","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.radonc.2019.06.036","article-title":"High efficacy of hypofractionated proton therapy with 4 fractions of 5 gy as a boost to 50 gy photon therapy for localized prostate cancer","volume":"141","author":"Johansson","year":"2019","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13014-019-1210-7","article-title":"Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation","volume":"14","author":"Ha","year":"2019","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0165","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ijrobp.2021.02.014","article-title":"Ultrahypofractionated proton radiation therapy in the treatment of low and intermediate-risk prostate Cancer-5-year outcomes","volume":"110","author":"Kube\u0161","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0170","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/1754-9485.12947","article-title":"Extreme hypofractionated proton radiotherapy for prostate cancer using pencil beam scanning: dosimetry, acute toxicity and preliminary results","volume":"63","author":"Kube\u0161","year":"2019","journal-title":"Journal of Medical Imaging and Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/COC.0000000000000241","article-title":"Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: interim results of a randomized trial PCG GU 002","volume":"41","author":"Vargas","year":"2018","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.euros.2021.01.011","article-title":"Comparative survival outcomes of high-risk prostate cancer treated with radical prostatectomy or definitive radiotherapy regimens","volume":"26","author":"Aas","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.radonc.2024.110264_b0185","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ijrobp.2004.07.695","article-title":"Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding","volume":"60","author":"Akimoto","year":"2004","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0190","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0195","article-title":"Effect of large prostate volume on efficacy and toxicity of moderately hypofractionated radiation therapy in patients with prostate cancer","volume":"7","author":"Natesan","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110264_b0200","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14740\/wjon986w","article-title":"Rectal toxicity after extremely hypofractionated radiotherapy using a non-isocentric robotic radiosurgery system for early stage prostate cancer","volume":"7","author":"Shikama","year":"2016","journal-title":"World J Oncol"},{"key":"10.1016\/j.radonc.2024.110264_b0205","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s12253-019-00623-2","article-title":"Acute and late toxicity after moderate hypofractionation with simultaneous integrated boost (SIB) radiation therapy for prostate cancer. a single institution, prospective study","volume":"26","author":"Jorgo","year":"2020","journal-title":"Pathology Oncology Research"},{"key":"10.1016\/j.radonc.2024.110264_b0210","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00432-019-02893-4","article-title":"Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter?","volume":"145","author":"Achard","year":"2019","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0215","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.7150\/jca.35510","article-title":"The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial","volume":"10","author":"Alexidis","year":"2019","journal-title":"Journal of Cancer"},{"key":"10.1016\/j.radonc.2024.110264_b0220","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.7150\/jca.37825","article-title":"Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer","volume":"11","author":"Alexidis","year":"2020","journal-title":"Journal of Cancer"},{"key":"10.1016\/j.radonc.2024.110264_b0225","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.radonc.2021.06.033","article-title":"Anorectal dose-effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial","volume":"162","author":"Groen","year":"2021","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0230","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.radonc.2017.12.022","article-title":"Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial","volume":"127","author":"Monninkhof","year":"2018","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0240","first-page":"763","article-title":"A hypofractionated radiotherapy schedule with 57.75Gy in 21 fractions for T1\u20132N0 prostate carcinoma: analysis of late toxicity and efficacy","volume":"19","author":"Kouloulias","year":"2014","journal-title":"Journal of B.U.ON."},{"key":"10.1016\/j.radonc.2024.110264_b0245","doi-asserted-by":"crossref","first-page":"435","DOI":"10.5507\/bp.2016.008","article-title":"Early toxicity of hypofractionated radiotherapy for prostate cancer","volume":"160","author":"Krupa","year":"2016","journal-title":"Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic"},{"key":"10.1016\/j.radonc.2024.110264_b0250","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/j.clon.2021.08.010","article-title":"Moderately hypofractionated radiotherapy and androgen deprivation therapy for high-risk localised prostate cancer: predictors of long-term biochemical control and toxicity","volume":"34","author":"Maulik","year":"2022","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"key":"10.1016\/j.radonc.2024.110264_b0255","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0260","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0265","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","year":"2015","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0270","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.clon.2016.02.005","article-title":"Moderate hypofractionation with simultaneous integrated boost in prostate cancer: long-term results of a phase I-II study","volume":"28","author":"Di Muzio","year":"2016","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"key":"10.1016\/j.radonc.2024.110264_b0275","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bju.14925","article-title":"Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial","volume":"125","author":"Macias","year":"2020","journal-title":"BJU International"},{"key":"10.1016\/j.radonc.2024.110264_b0280","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12032-020-01397-3","article-title":"Phase II prospective trial \u00abgive me five\u00bb short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218)","volume":"37","author":"Marvaso","year":"2020","journal-title":"Medical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0285","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijrobp.2019.07.027","article-title":"Comparison of outcomes and toxicity between extreme and moderate radiation therapy hypofractionation in localized prostate cancer: a propensity score analysis","volume":"105","author":"Marvaso","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0290","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.prro.2021.02.011","article-title":"Clinical outcomes of the CHIRP trial: a phase II prospective randomized trial of conventionally fractionated versus moderately hypofractionated prostate and pelvic nodal radiation therapy in patients with high-risk prostate cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Practical Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0295","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2019.03.002","article-title":"Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): results from a prospective clinical trial","volume":"135","author":"Alayed","year":"2019","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0300","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.radonc.2018.02.029","article-title":"Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): a phase 2 randomized trial","volume":"127","author":"Quon","year":"2018","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0305","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2013.03.022","article-title":"Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes","volume":"107","author":"Loblaw","year":"2013","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0310","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/cncr.26699","article-title":"Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial","volume":"118","author":"McBride","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110264_b0315","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1748-717X-8-30","article-title":"Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer","volume":"8","author":"Ju","year":"2013","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0320","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/030089161109700109","article-title":"Image-guided stereotactic body radiation therapy for localized prostate cancer","volume":"97","author":"Kang","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.radonc.2024.110264_b0325","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0330","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1748-717X-8-84","article-title":"Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results","volume":"8","author":"Aluwini","year":"2013","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0335","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0340","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2010.10.026","article-title":"Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response","volume":"82","author":"Jabbari","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0345","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13014-016-0758-8","article-title":"Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer","volume":"12","author":"Boyer","year":"2017","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0350","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3389\/fonc.2014.00319","article-title":"Stereotactic body radiation therapy for prostate cancer: review of experience of a multicenter phase I\/II dose-escalation study","volume":"4","author":"Kim","year":"2014","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0355","doi-asserted-by":"crossref","unstructured":"Bernetich M, Oliai C, Lanciano R, Hanlon A, Lamond J, Arrigo S, et al. SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines. Front Oncol 2014;4:312.","DOI":"10.3389\/fonc.2014.00312"},{"key":"10.1016\/j.radonc.2024.110264_b0360","first-page":"e173","volume":"28","author":"D\u2019Agostino","year":"2016","journal-title":"High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer A Mono-institutional Experience with 90 Patients"},{"key":"10.1016\/j.radonc.2024.110264_b0365","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1533034614566994","article-title":"High-dose robotic stereotactic body radiotherapy in the treatment of patients with prostate cancer: preliminary results in 26 patients","volume":"15","author":"Pontoriero","year":"2016","journal-title":"Technology in Cancer Research & Treatment"},{"key":"10.1016\/j.radonc.2024.110264_b0370","doi-asserted-by":"crossref","first-page":"297","DOI":"10.18869\/acadpub.ijrr.14.4.297","article-title":"Prostate-specific antigen kinetics after hypofractionated stereotactic body radiotherapy for localized prostate cancer","volume":"14","author":"Kim","year":"2016","journal-title":"International Journal of Radiation Research"},{"key":"10.1016\/j.radonc.2024.110264_b0375","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1748-717X-8-118","article-title":"Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years","volume":"8","author":"Katz","year":"2013","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0380","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/MD.0000000000000290","article-title":"Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: a 5-year follow-up of an investigational study","volume":"93","author":"Lee","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.radonc.2024.110264_b0385","doi-asserted-by":"crossref","first-page":"684","DOI":"10.5301\/tj.5000355","article-title":"Stereotactic ablative radiotherapy with CyberKnife in the treatment of locally advanced prostate cancer: preliminary results","volume":"101","author":"Fan","year":"2015","journal-title":"Tumori"},{"key":"10.1016\/j.radonc.2024.110264_b0390","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jmrs.205","article-title":"First australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life","volume":"64","author":"Dixit","year":"2017","journal-title":"Journal of Medical Radiation Sciences"},{"key":"10.1016\/j.radonc.2024.110264_b0395","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ijrobp.2016.02.009","article-title":"Dose-escalated stereotactic body radiation therapy for patients with intermediate- and high-risk prostate cancer: initial dosimetry analysis and patient outcomes","volume":"95","author":"Kotecha","year":"2016","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0400","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.adro.2019.07.007","article-title":"A phase I\/II trial of fairly brief androgen suppression and stereotactic radiation therapy for high-risk prostate cancer (FASTR-2): preliminary results and toxicity analysis","volume":"4","author":"Callan","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110264_b0405","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/153303461000900505","article-title":"Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results","volume":"9","author":"Bolzicco","year":"2010","journal-title":"Technology in Cancer Research & Treatment"},{"key":"10.1016\/j.radonc.2024.110264_b0410","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fonc.2014.00336","article-title":"A phase II study of stereotactic body radiation therapy for low-intermediate-high-risk prostate cancer using helical tomotherapy: dose-volumetric parameters predicting early toxicity","volume":"4","author":"Macias","year":"2014","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0415","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.prnil.2015.12.001","article-title":"Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer","volume":"4","author":"Phak","year":"2016","journal-title":"Prostate International"},{"key":"10.1016\/j.radonc.2024.110264_b0420","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.euo.2019.09.006","article-title":"Early tolerance and tumor control outcomes with high-dose ultrahypofractionated radiation therapy for prostate cancer","volume":"3","author":"Zelefsky","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2024.110264_b0425","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.3390\/cancers13194866","article-title":"1.5T magnetic resonance-guided stereotactic body radiotherapy for localized prostate cancer: preliminary clinical results of clinician- and patient-reported outcomes","volume":"13","author":"Poon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2024.110264_b0430","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3389\/fonc.2020.01505","article-title":"Favorable biochemical freedom from recurrence with stereotactic body radiation therapy for intermediate and high-risk prostate cancer: a single institutional experience with long-term follow-up","volume":"10","author":"Ricco","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0435","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.radonc.2017.03.006","article-title":"Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: is there an optimal dose?","volume":"123","author":"Helou","year":"2017","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0440","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2478\/raon-2021-0031","article-title":"Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study","volume":"55","author":"Jorgo","year":"2021","journal-title":"Radiology and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0445","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ijrobp.2019.04.006","article-title":"Stereotactic body radiation therapy boost for intermediate-risk prostate cancer: a phase 1 dose-escalation study","volume":"104","author":"Alayed","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0450","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/COC.0000000000000721","article-title":"Stereotactic body radiation therapy for intermediate-risk prostate cancer with VMAT and real-time electromagnetic tracking: a phase II study","volume":"43","author":"D\u2019Agostino","year":"2020","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0455","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s11547-020-01216-9","article-title":"Short fractionation radiotherapy for early prostate cancer in the time of COVID-19: long-term excellent outcomes from a multicenter italian trial suggest a larger adoption in clinical practice","volume":"126","author":"Barra","year":"2021","journal-title":"La Radiologia Medica"},{"key":"10.1016\/j.radonc.2024.110264_b0460","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: early toxicity results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0465","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s13566-016-0249-4","article-title":"A phase II experience evaluating quality of life and survival in linac-based SBRT for prostate cancer","volume":"5","author":"DeNittis","year":"2016","journal-title":"Journal of Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0470","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/13685538.2021.1948992","article-title":"The efficacy and tolerability of ultra-hypofractionated radiotherapy in low-intermediate risk prostate cancer patients: single center experience","volume":"24","author":"Din\u00e7er","year":"2021","journal-title":"The Aging Male"},{"key":"10.1016\/j.radonc.2024.110264_b0475","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4149\/neo_2015_081","article-title":"Acute toxicity of robotic ultrahypofractionated radiotherapy CyberKnifeTM in prostate cancer patients","volume":"62","author":"Glowacki","year":"2015","journal-title":"Neoplasma"},{"key":"10.1016\/j.radonc.2024.110264_b0480","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.ijrobp.2020.11.003","article-title":"Biochemical control and toxicity outcomes of stereotactic body radiation therapy versus low-dose-rate brachytherapy in the treatment of low- and intermediate-risk prostate cancer","volume":"109","author":"Gogineni","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0485","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13014-019-1346-5","article-title":"Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes","volume":"14","author":"Hwang","year":"2019","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0490","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13014-019-1369-y","article-title":"A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer","volume":"14","author":"Kainuma","year":"2019","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0495","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13014-022-02037-y","article-title":"A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer","volume":"17","author":"Kawakami","year":"2022","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0500","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fonc.2017.00157","article-title":"Prostate-specific antigen 5 years following stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: an ablative procedure?","volume":"7","author":"Kataria","year":"2017","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0505","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ijrobp.2020.03.014","article-title":"Real-time image guided ablative prostate cancer radiation therapy: results from the TROG 15.01 SPARK trial","volume":"107","author":"Keall","year":"2020","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0510","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4111\/kju.2014.55.3.172","article-title":"Clinical outcomes of CyberKnife radiotherapy in prostate cancer patients: short-term","volume":"55","author":"Koh","year":"2014","journal-title":"Single-Center Experience Korean J Urol"},{"key":"10.1016\/j.radonc.2024.110264_b0515","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13014-021-01908-0","article-title":"Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking","volume":"16","author":"Lucchini","year":"2021","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0520","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819870815","article-title":"Stereotactic ablative radiotherapy for prostate cancer-the treatment results of 500 patients and analysis of failures","volume":"18","author":"Miszczyk","year":"2019","journal-title":"Technology in Cancer Research & Treatment"},{"key":"10.1016\/j.radonc.2024.110264_b0525","first-page":"88","article-title":"Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: initial results of the SPARC trial","volume":"25","author":"Nicholls","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110264_b0530","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00066-018-1338-7","article-title":"Phase II study of accelerated linac-based SBRT in five consecutive fractions for localized prostate cancer","volume":"195","author":"Alongi","year":"2019","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1016\/j.radonc.2024.110264_b0535","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00432-019-02983-3","article-title":"Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients","volume":"145","author":"Nicosia","year":"2019","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0540","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13014-021-01834-1","article-title":"Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison","volume":"16","author":"Ogita","year":"2021","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0545","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/COC.0000000000000693","article-title":"Heterogenous dose-escalated prostate stereotactic body radiation therapy for all risk prostate cancer: quality of life and clinical outcomes of an institutional pilot study","volume":"43","author":"Parsai","year":"2020","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0550","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijrobp.2019.01.092","article-title":"Outcomes of a dose-escalated stereotactic body radiation phase 1 trial for patients with low- and intermediate-risk prostate cancer","volume":"104","author":"Potters","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0555","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/j.prro.2015.02.001","article-title":"Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Seymour","year":"2015","journal-title":"Practical Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0560","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2021.02.028","article-title":"Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: high-dose-rate brachytherapy vs stereotactic ablative radiotherapy","volume":"158","author":"Tsang","year":"2021","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0565","doi-asserted-by":"crossref","first-page":"20200696","DOI":"10.1259\/bjr.20200696","article-title":"Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity","volume":"94","author":"Ugurluer","year":"2021","journal-title":"The British Journal of Radiology"},{"key":"10.1016\/j.radonc.2024.110264_b0570","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13014-020-01608-1","article-title":"Stereotactic body radiotherapy for localized prostate cancer - 5-year efficacy results","volume":"15","author":"Vuolukka","year":"2020","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0575","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1007\/s00432-021-03785-2","article-title":"Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China","volume":"147","author":"Zhao","year":"2021","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0580","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00066-020-01619-7","article-title":"Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : long-term results and factors predictive for outcome and toxicity","volume":"196","author":"Franzese","year":"2020","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1016\/j.radonc.2024.110264_b0585","doi-asserted-by":"crossref","first-page":"20190021","DOI":"10.1259\/bjr.20190021","article-title":"Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity","volume":"92","author":"Franzese","year":"2019","journal-title":"The British Journal of Radiology"},{"key":"10.1016\/j.radonc.2024.110264_b0590","doi-asserted-by":"crossref","first-page":"13194","DOI":"10.1038\/s41598-021-92307-8","article-title":"Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for japanese prostate cancer patients","volume":"11","author":"Ishiyama","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/j.radonc.2024.110264_b0595","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/jjco\/hyab094","article-title":"Stereotactic body radiation therapy for japanese patients with localized prostate cancer: 2-year results and predictive factors for acute genitourinary toxicities","volume":"51","author":"Ito","year":"2021","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0600","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.21873\/anticanres.15030","article-title":"Comparison of physician-recorded toxicities and patient-reported outcomes of five different radiotherapy methods for prostate cancer","volume":"41","author":"Ito","year":"2021","journal-title":"Anticancer Research"},{"key":"10.1016\/j.radonc.2024.110264_b0605","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s10147-020-01855-y","article-title":"Distribution analysis of hydrogel spacer and evaluation of rectal dose reduction in japanese prostate cancer patients undergoing stereotactic body radiation therapy","volume":"26","author":"Kobayashi","year":"2021","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0610","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/ajco.12566","article-title":"Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer","volume":"12","author":"Lee","year":"2016","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0615","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clon.2019.09.046","article-title":"A phase I\/II study of stereotactic hypofractionated once-weekly radiation therapy (SHORT) for prostate cancer","volume":"32","author":"Mallick","year":"2020","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"key":"10.1016\/j.radonc.2024.110264_b0620","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.21873\/anticanres.14162","article-title":"Stereotactic body radiotherapy using CyberKnife\u00ae for localized low- and intermediate-risk prostate cancer: initial report on a phase I\/II trial","volume":"40","author":"Nakamura","year":"2020","journal-title":"Anticancer Research"},{"key":"10.1016\/j.radonc.2024.110264_b0625","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13014-018-1182-z","article-title":"Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (korean radiation oncology group study 15\u201301)","volume":"13","author":"Park","year":"2018","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0630","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/curroncol29010003","article-title":"Prospective randomized phase II study of stereotactic body radiotherapy (SBRT) vs. conventional fractionated radiotherapy (CFRT) for chinese patients with early-stage localized prostate cancer","volume":"29","author":"Poon","year":"2021","journal-title":"Current Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0635","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.vhri.2016.08.001","article-title":"Conventionally fractionationed volumetric arc therapy versus hypofractionated stereotactic body radiotherapy: quality of life, side effects, and prostate-specific antigen kinetics in localized prostate cancer","volume":"10","author":"Tambas","year":"2016","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.radonc.2024.110264_b0640","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 gy in five fractions for localized disease: first clinical trial results","volume":"67","author":"Madsen","year":"2007","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0645","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00066-016-0971-2","article-title":"SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : toxicity and quality of life assessment","volume":"192","author":"Rucinska","year":"2016","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1016\/j.radonc.2024.110264_b0650","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/cancers14010195","article-title":"Ultrahypofractionated radiotherapy versus conventional to moderate hypofractionated radiotherapy for clinically localized prostate cancer","volume":"14","author":"Yamazaki","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2024.110264_b0655","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1\u20132 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): early toxicity and quality of life","volume":"102","author":"Musunuru","year":"2018","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0660","doi-asserted-by":"crossref","first-page":"306","DOI":"10.21873\/invivo.12703","article-title":"Stereotactic radiotherapy and androgen deprivation therapy for localized prostate cancer: a retrospective mono-institutional experience","volume":"36","author":"Magli","year":"2022","journal-title":"In Vivo"},{"key":"10.1016\/j.radonc.2024.110264_b0665","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2021.03.027","article-title":"Toxicity at 1 year after stereotactic body radiation therapy in 3 fractions for localized prostate cancer","volume":"111","author":"Magli","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0670","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.clon.2008.08.006","article-title":"Phase I\/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3","volume":"20","author":"Tang","year":"2008","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"key":"10.1016\/j.radonc.2024.110264_b0675","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","article-title":"Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer","volume":"36","author":"Hoffman","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0680","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0685","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0690","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","article-title":"Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): a randomised trial","volume":"145","author":"Murthy","year":"2020","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0695","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/1748-717X-8-206","article-title":"A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients","volume":"8","author":"Norkus","year":"2013","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0700","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1748-717X-2-29","article-title":"Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I\/II feasibility study","volume":"2","author":"Junius","year":"2007","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0705","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2010.04.054","article-title":"A phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer","volume":"80","author":"Lock","year":"2011","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0710","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijrobp.2005.07.970","article-title":"Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial","volume":"64","author":"Pollack","year":"2006","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0715","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00066-013-0443-x","article-title":"Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT","volume":"190","author":"Guckenberger","year":"2014","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1016\/j.radonc.2024.110264_b0720","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.radonc.2016.10.017","article-title":"Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer","volume":"122","author":"Lieng","year":"2017","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0725","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jrr\/rry089","article-title":"Long-term results of intensity-modulated radiotherapy with three dose-fractionation regimens for localized prostate cancer","volume":"60","author":"Takemoto","year":"2019","journal-title":"Journal of Radiation Research"},{"key":"10.1016\/j.radonc.2024.110264_b0730","first-page":"11","article-title":"Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer","volume":"38","author":"Teh","year":"2018","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.radonc.2024.110264_b0735","first-page":"293","article-title":"Early toxicity of moderate hypofractionated volumetric modulated arc radiotherapy for localized prostate cancer","volume":"17","author":"Kim","year":"2019","journal-title":"International Journal of Radiation Research"},{"key":"10.1016\/j.radonc.2024.110264_b0740","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11604-017-0630-2","article-title":"Acute and late complications after hypofractionated intensity modulated radiotherapy in prostate cancer","volume":"35","author":"Kozuka","year":"2017","journal-title":"Japanese Journal of Radiology"},{"key":"10.1016\/j.radonc.2024.110264_b0745","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.3747\/co.22.2247","article-title":"Acute toxicity of hypofractionated intensity-modulated radiotherapy for prostate cancer","volume":"22","author":"Drodge","year":"2015","journal-title":"Current Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0750","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.prro.2017.09.007","article-title":"Phase 1\/2 study of hypofractionated intensity-modulated radiation therapy for prostate cancer including simultaneously integrated boost","volume":"8","author":"Chang","year":"2018","journal-title":"Practical Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0755","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.meddos.2016.10.002","article-title":"Acute toxicity and its dosimetric correlates for high-risk prostate cancer treated with moderately hypofractionated radiotherapy","volume":"42","author":"Arunsingh","year":"2017","journal-title":"Medical Dosimetry"},{"key":"10.1016\/j.radonc.2024.110264_b0760","doi-asserted-by":"crossref","first-page":"3170396","DOI":"10.1155\/2020\/3170396","article-title":"Moderately hypofractionated radiotherapy with simultaneous integrated boost in prostate cancer: a comparative study with conventionally fractionated radiation","volume":"2020","author":"Cante","year":"2020","journal-title":"Journal of Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0765","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12094-019-02224-6","article-title":"Influence of the technique and comorbidities in hypofractionated radiotherapy for prostate cancer","volume":"22","author":"Correa","year":"2020","journal-title":"Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the Cancer Institute of Mexico"},{"key":"10.1016\/j.radonc.2024.110264_b0770","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10147-017-1175-1","article-title":"The 5-year outcomes of moderately hypofractionated radiotherapy (66 gy in 22 fractions, 3 fractions per week) for localized prostate cancer: a retrospective study","volume":"23","author":"Hashimoto","year":"2018","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0775","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijrobp.2019.01.091","article-title":"Ten-year outcomes of moderately hypofractionated (70 gy in 28 fractions) intensity modulated radiation therapy for localized prostate cancer","volume":"104","author":"Abu-Gheida","year":"2019","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0780","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.ijrobp.2007.01.067","article-title":"Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 gy per fraction) for localized prostate cancer: Cleveland Clinic experience","volume":"68","author":"Kupelian","year":"2007","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0785","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijrobp.2015.10.055","article-title":"Moderate hypofractionated protracted radiation therapy and dose escalation for prostate cancer: do dose and overall treatment time matter?","volume":"94","author":"Kountouri","year":"2016","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0790","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.21873\/invivo.11595","article-title":"Hypofractionated intensity-modulated radiotherapy for intermediate- and high-risk prostate cancer: a retrospective study","volume":"33","author":"Kubo","year":"2019","journal-title":"In Vivo"},{"key":"10.1016\/j.radonc.2024.110264_b0795","doi-asserted-by":"crossref","first-page":"e0211370","DOI":"10.1371\/journal.pone.0211370","article-title":"Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: a retrospective study","volume":"14","author":"Takakusagi","year":"2019","journal-title":"PLoS One1"},{"key":"10.1016\/j.radonc.2024.110264_b0800","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.21873\/invivo.12637","article-title":"Clinical outcomes of hydrogel spacer injection space OAR in men submitted to hypofractionated radiotherapy for prostate cancer","volume":"35","author":"Pepe","year":"2021","journal-title":"In Vivo"},{"key":"10.1016\/j.radonc.2024.110264_b0805","first-page":"385","article-title":"Long-term outcomes of a dose-reduction trial to decrease late gastrointestinal toxicity in patients with prostate cancer receiving soft tissue-matched image-guided intensity-modulated radiotherapy","volume":"38","author":"Sasaki","year":"2018","journal-title":"Anticancer Research"},{"key":"10.1016\/j.radonc.2024.110264_b0810","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.18632\/aging.202551","article-title":"Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China","volume":"13","author":"Zhong","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.radonc.2024.110264_b0815","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.prro.2017.01.003","article-title":"Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy","volume":"7","author":"Faria","year":"2017","journal-title":"Practical Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0820","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2020.01.029","article-title":"Target motion mitigation promotes high-precision treatment planning and delivery of extreme hypofractionated prostate cancer radiotherapy: results from a phase II study","volume":"146","author":"Greco","year":"2020","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0825","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3857\/roj.2016.34.1.45","article-title":"Hypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study","volume":"34","author":"Kang","year":"2016","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.radonc.2024.110264_b0830","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13566-015-0181-z","article-title":"Hypofractionated intensity-modulated radiation therapy for prostate cancer confined to the pelvis: analysis of efficacy and late toxicity","volume":"4","author":"Liu","year":"2015","journal-title":"Journal of Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0835","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/jrr\/rry060","article-title":"A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer","volume":"59","author":"Nakamura","year":"2018","journal-title":"Journal of Radiation Research"},{"key":"10.1016\/j.radonc.2024.110264_b0840","first-page":"5829","article-title":"Long-term tumor control and late toxicity in patients with prostate cancer receiving hypofractionated (2.2 gy) soft-tissue-matched image-guided intensity-modulated radiotherapy","volume":"37","author":"Shimizu","year":"2017","journal-title":"Anticancer Research"},{"key":"10.1016\/j.radonc.2024.110264_b0845","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1748-717X-9-118","article-title":"Early results of urethral dose reduction and small safety margin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using a real-time tumor-tracking radiotherapy (RTRT) system","volume":"9","author":"Shimizu","year":"2014","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0850","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.clon.2020.02.004","article-title":"Comparison of treatment-related toxicity with hypofractionated or conventionally fractionated radiation therapy for prostate cancer: a National Population-Based Study","volume":"32","author":"Sujenthiran","year":"2020","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"key":"10.1016\/j.radonc.2024.110264_b0855","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.21873\/anticanres.12716","article-title":"Long-term outcomes of radiotherapy regimen of 72 gy in 30 fractions for prostate cancer","volume":"38","author":"Tamari","year":"2018","journal-title":"Anticancer Research"},{"key":"10.1016\/j.radonc.2024.110264_b0860","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1017\/S146039691200043X","article-title":"Outcome and patient-reported toxicity in localised prostate cancer treated with dose-escalated hypofractionated intensity-modulated radiotherapy","volume":"12","author":"Thomson","year":"2013","journal-title":"Journal of Radiotherapy in Practice"},{"key":"10.1016\/j.radonc.2024.110264_b0865","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.29983","article-title":"Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial","volume":"122","author":"Viani","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110264_b0870","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.adro.2017.12.006","article-title":"Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer","volume":"3","author":"Wang","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110264_b0875","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1017\/S1460396920000175","article-title":"Two-year outcomes of moderately hypofractionated 70 gy in 28 fractions, intensity-modulated radiotherapy and volumetric modulated arc therapy for localised prostate cancer","volume":"20","author":"Ortiz Arce","year":"2021","journal-title":"Journal of Radiotherapy in Practice"},{"key":"10.1016\/j.radonc.2024.110264_b0880","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0885","doi-asserted-by":"crossref","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.radonc.2024.110264_b0890","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0895","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijrobp.2018.06.008","article-title":"Patient reported outcomes in NRG oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer","volume":"102","author":"Lukka","year":"2018","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0900","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.ijrobp.2021.01.043","article-title":"A pooled toxicity analysis of moderately hypofractionated proton beam therapy and intensity modulated radiation therapy in early-stage prostate cancer patients","volume":"110","author":"Vapiwala","year":"2021","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0905","article-title":"Clinical efficacy and safety of proton and carbon ion radiotherapy for prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0910","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.937934","article-title":"High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer","volume":"12","author":"Joseph","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0915","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.3390\/cancers15184571","article-title":"5-years analysis of effectivity and toxicity of ultra-hypofractionated proton radiotherapy in the treatment of low- and intermediate-risk prostate cancer\u2014A retrospective analysis","volume":"15","author":"Kube\u0161","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2024.110264_b0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109854","article-title":"Proton therapy for the management of localized prostate cancer: long-term clinical outcomes at a comprehensive cancer center","volume":"188","author":"Sosa","year":"2023","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0925","doi-asserted-by":"crossref","first-page":"R419","DOI":"10.1088\/0031-9155\/59\/22\/R419","article-title":"Relative biological effectiveness (RBE) values for proton beam therapy. variations as a function of biological endpoint, dose, and linear energy transfer","volume":"59","author":"Paganetti","year":"2014","journal-title":"Physics in Medicine and Biology"},{"key":"10.1016\/j.radonc.2024.110264_b0930","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ab2144","article-title":"Applying a variable relative biological effectiveness (RBE) might affect the analysis of clinical trials comparing photon and proton therapy for prostate cancer","volume":"64","author":"Marteinsdottir","year":"2019","journal-title":"Physics in Medicine and Biology"},{"key":"10.1016\/j.radonc.2024.110264_b0935","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3390\/cancers14030681","article-title":"A decision support tool to optimize selection of head and neck cancer patients for proton therapy","volume":"14","author":"Tambas","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2024.110264_b0940","first-page":"35","article-title":"Relative biological effectiveness in proton beam therapy - current knowledge and future challenges","volume":"9","author":"L\u00fchr","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110264_b0945","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/153303460300200506","article-title":"Significance and implementation of RBE variations in proton beam therapy","volume":"2","author":"Paganetti","year":"2003","journal-title":"Technology in Cancer Research & Treatment"},{"key":"10.1016\/j.radonc.2024.110264_b0950","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.clon.2023.02.009","article-title":"Outcomes of patients treated in the UK proton overseas programme: non-central nervous system group","volume":"35","author":"Hwang","year":"2023","journal-title":"Clinical Oncology (Royal College of Radiologists)"},{"key":"10.1016\/j.radonc.2024.110264_b0955","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.3390\/cancers15092489","article-title":"Proton beam therapy in the oligometastatic\/oligorecurrent setting: is there a role?","volume":"15","author":"Gaito","year":"2023","journal-title":"A Literature Review Cancers (Basel)"},{"key":"10.1016\/j.radonc.2024.110264_b0960","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2007.03.018","article-title":"Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison","volume":"69","author":"Trofimov","year":"2007","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0965","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ijrobp.2007.07.2335","article-title":"Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer","volume":"70","author":"Vargas","year":"2008","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0970","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0360-3016(00)01368-7","article-title":"Potential role of intensity modulated proton beams in prostate cancer radiotherapy","volume":"49","author":"Cella","year":"2001","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0975","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00066-005-1317-7","article-title":"Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy","volume":"181","author":"Mock","year":"2005","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1016\/j.radonc.2024.110264_b0980","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ijrobp.2009.01.044","article-title":"Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer","volume":"75","author":"Chera","year":"2009","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2024.110264_b0985","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(11)70141-3","article-title":"Delivering affordable cancer care in high-income countries","volume":"12","author":"Sullivan","year":"2011","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b0990","doi-asserted-by":"crossref","first-page":"20210670","DOI":"10.1259\/bjr.20210670","article-title":"Proton therapy for prostate cancer: current state and future perspectives","volume":"95","author":"Wu","year":"2022","journal-title":"The British Journal of Radiology"},{"key":"10.1016\/j.radonc.2024.110264_b0995","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tipsro.2019.08.001","article-title":"Proton therapy- the modality of choice for future radiation therapy management of prostate cancer?","volume":"11","author":"Mangan","year":"2019","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110264_b1000","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/j.clon.2023.05.014","article-title":"Assessing equity of access to proton beam therapy: a literature review","volume":"35","author":"Gaito","year":"2023","journal-title":"Clinical Oncology"},{"key":"10.1016\/j.radonc.2024.110264_b1005","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2017.03.028","article-title":"Cost of new Technologies in Prostate Cancer Treatment: systematic review of costs and cost effectiveness of robotic-assisted laparoscopic prostatectomy, intensity-modulated radiotherapy, and proton beam therapy","volume":"72","author":"Schroeck","year":"2017","journal-title":"European Urology"},{"key":"10.1016\/j.radonc.2024.110264_b1010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1186\/s12913-016-1781-z","article-title":"Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review","volume":"16","author":"Becerra","year":"2016","journal-title":"BMC Health Services Research"},{"key":"10.1016\/j.radonc.2024.110264_b1015","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(19)30794-6","article-title":"How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement","volume":"21","author":"Lievens","year":"2020","journal-title":"The Lancet Oncology"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024001865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024001865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T17:40:37Z","timestamp":1741455637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024001865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":203,"alternative-id":["S0167814024001865"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110264","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110264"}}